Key PointsModerna’s personalized melanoma vaccine, paired with Merck’s Keytruda, cut the risk of recurrence or death by 42% in a Phase 3 trial.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
